Background: Systemic Sclerosis-SSc is an autoimmune disease, characterized by fibrosis due to immune-mediated microangiopathy. Digital ulcers-DUs represent frequent complications, they are recurrent, painful and often resistant to traditional treatments. Standard therapy, in particular oral opioids, is often inadequate or limited by side effect. Cannabidiol-CBD, is the major non-psychotropic component of the Cannabis sativa, recent studies on its effectiveness as an anxiolytic, anti-inflammatory, and antipsychotic drug showed promising results, in the setting of chronic pain too. Objectives: We evaluated the efficacy of CBD drop in pain management in a cohort of SSc patients using standard rating scale VAS, PSQI and HAQ. We further assessed the safety profile and the potential use as opioid-sparing. Methods: From January to November 2019 we consecutively enrolled 31 SSc patients (F/M 26/5, mean age 53.0 …
POS0837 THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS / Giuggioli, D.; De Pinto, M.; Parenti, L.; Magnani, L.; Castrignanò, P.; Salvarani, C.; 2, ; Spinella, A.. - 80:(2021), pp. 672-673. (Intervento presentato al convegno EULAR 2021 tenutosi a on line nel 2021).
POS0837 THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS
D. Giuggioli;M. De Pinto;P. Castrignanò;C. Salvarani;A. Spinella
2021
Abstract
Background: Systemic Sclerosis-SSc is an autoimmune disease, characterized by fibrosis due to immune-mediated microangiopathy. Digital ulcers-DUs represent frequent complications, they are recurrent, painful and often resistant to traditional treatments. Standard therapy, in particular oral opioids, is often inadequate or limited by side effect. Cannabidiol-CBD, is the major non-psychotropic component of the Cannabis sativa, recent studies on its effectiveness as an anxiolytic, anti-inflammatory, and antipsychotic drug showed promising results, in the setting of chronic pain too. Objectives: We evaluated the efficacy of CBD drop in pain management in a cohort of SSc patients using standard rating scale VAS, PSQI and HAQ. We further assessed the safety profile and the potential use as opioid-sparing. Methods: From January to November 2019 we consecutively enrolled 31 SSc patients (F/M 26/5, mean age 53.0 …
| File | Dimensione | Formato | |
|---|---|---|---|
|
poster eular 2021 CBD .pdf
Open access
Tipologia:
Versione pubblicata dall'editore
Dimensione
254.82 kB
Formato
Adobe PDF
|
254.82 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
